Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.60 |
| ▸ | FLT1 | P17948 | 10/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033477 | 0.99 | ABL1 (0.58) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL13033829 | 0.90 | FGFR1 (0.50) | ABL1FGFR1FLT1KDRKDM4E | |
| SCHEMBL13033553 | 0.90 | FGFR1 (0.51) | ABL1FGFR1FLT1KDRBCR | |
| SCHEMBL1624965 | 0.89 | LMNA (0.54) | ABL1FGFR1FLT1KDRKDM4E | |
| SCHEMBL13033687 | 0.88 | FGFR1 (0.46) | ABL1FGFR1FLT1KDRKDM4E | |
| SCHEMBL1625564 | 0.86 | LMNA (0.49) | ABL1FGFR1FLT1KDM4ENPC1 | |
| SCHEMBL16328077 | 0.85 | TRPC3 (0.55) | ABL1FGFR1FLT1KDRKDM4E | |
| SCHEMBL3511829 | 0.85 | KDM4E (0.51) | ABL1FGFR1FLT1KDM4ENPC1 | |
| SCHEMBL13033398 | 0.85 | SSTR2 (0.54) | ABL1FGFR1FLT1KDRKDM4E | |
| SCHEMBL13033686 | 0.84 | KDM4E (0.44) | ABL1FGFR1FLT1KDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592463-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | ABL1 1305/4885FGFR1 222/4885FLT1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.